Erratum: South African guideline for the management of community-acquired pneumonia in adults (Journal of Thoracic Disease (2017) 9 (1469-1502) DOI: 10.21037/jtd.2017.05.31);South African guideline for the management of communityacquired pneumonia in adults

Journal of Thoracic Disease

Volumn 9, Issue 6, 2017, Pages 1469-1502

  Boyles, Tom H ^a   Brink, Adrian ^a,b   Calligaro, Greg L ^c   Cohen, Cheryl ^d,e   Dheda, Keertan ^c   Maartens, Gary ^a   Richards, Guy A ^f   Smit, Richard van Zyl ^c   Smith, Clifford ^g   Wasserman, Sean ^a   Whitelaw, Andrew C ^h,i   Feldman, Charles ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g Morningside Mediclinic   (South Africa)

^h UNIVERSITY OF STELLENBOSCH   (South Africa)

ⁱ STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFOTAXIME; CEFPODOXIME; CEFTAROLINE; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ACUTE HEART INFARCTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DECISION MAKING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; EMERGENCY WARD; EMPYEMA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA; LUNG ABSCESS; NONHUMAN; PATIENT CARE; PLEURA EFFUSION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; RISK FACTOR; SOUTH AFRICA; THORAX RADIOGRAPHY; TUBERCULOSIS; VACCINATION;

EID: 85021375961     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.21037/JTD.2018.07.137     Document Type: Erratum

References (218)

1. Foy HM, Cooney MK, Allan I, et al. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979;241:253-8
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88
3. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1:671-4
4. Brink A, Coetzee J, Clay C, et al. The spread of carbapenem-resistant Enterobacteriaceae in South Africa: risk factors for acquisition and prevention. S Afr Med J 2012;102:599-601
5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72
6. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64 Suppl 3:iii1-55
7. Working Group of the South African Thoracic Society. Management of community-acquired pneumonia in adults. S Afr Med J 2007;97:1296-306
8. Africa SS. Mortality and causes of death in South Africa, 2013: Findings from death notification P0309.3. Pretoria: Statistics South Africa, 2014
9. Cohen C, Walaza S, Moyes J, et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged >/=5 years in a high HIV-prevalence setting, 2009-2012. PLoS One 2015;10:e0117716
10. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8:e60273
11. von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014;371:1889-99
12. Cohen C, Dreyer A, Frean J, Treurnich F, Iyaloo S, Ismail N, et al. Respiratory pathogens from influenza-like illness and pneumonia surveillance programmes, South Africa 2014. Communicable Diseases Surveillance Bulletin 2015;13:10-30
13. Kang CI, Song JH, Oh WS, et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2008;27:657-61
14. Pretorius MA, Tempia S, Walaza S, et al. The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenza-like illness in a population with a high HIV sero-prevalence, South Africa 2012-2015. J Clin Virol 2016;75:21-6
15. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007;11:1308-13
16. Walaza S, Tempia S, Dawood H, et al. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. BMC Infect Dis 2015;15:26-015-0746-x
17. van Oosterhout JJ, Laufer MK, Graham SM, et al. A community-based study of the incidence of trimethoprimsulfamethoxazole-preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr 2005;39:626-31
18. Wasserman S, Engel ME, Griesel R, et al. Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis 2016;16:482-016-1809-3
19. Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med 2013;34:205-16
20. Al-Tawfiq JA, Zumla A, Gautret P, et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014;14:992-1000
21. Mandell, Douglas, and Bennett Principles and practice of infectious diseases. Philadelphia: Elsevier, 2010
22. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996;9:1590-5
23. Metlay JP, Stafford RS, Singer DE. National trends in the use of antibiotics by primary care physicians for adult patients with cough. Arch Intern Med 1998;158:1813-8
24. Diehr P, Wood RW, Bushyhead J, et al. Prediction of pneumonia in outpatients with acute cough-a statistical approach. J Chronic Dis 1984;37:215-25
25. Snow V, Mottur-Pilson C, Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001;134:518-20
26. Creer DD, Dilworth JP, Gillespie SH, et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006;61:75-9
27. Little P, Stuart B, Moore M, et al. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis 2013;13:123-9
28. Smith SM, Fahey T, Smucny J, et al. Antibiotics for acute bronchitis. Cochrane Database Syst Rev 2014;(3):CD000245
29. Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Semin Respir Infect 1999;14:151-62
30. Butler CC, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ 2009;338:b2242
31. Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA 2005;293:3029-35
32. Aabenhus R, Jensen JU, Jorgensen KJ, et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst Rev 2014;(11):CD010130
33. Brink AJ, Van Wyk J, Moodley VM, et al. The role of appropriate diagnostic testing in acute respiratory tract infections: An antibiotic stewardship strategy to minimise diagnostic uncertainty in primary care. S Afr Med J 2016;106:30-7
34. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18
35. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-5
36. O'Brien WT, Sr., Rohweder DA, Lattin GE Jr, et al. Clinical indicators of radiographic findings in patients with suspected community-acquired pneumonia: who needs a chest x-ray? J Am Coll Radiol 2006;3:703-6
37. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10
38. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332:1077-9
39. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age-and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002;165:766-72
40. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39:1642-50
41. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4
42. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000;31:1066-78
43. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with communityacquired pneumonia. Arch Intern Med 1997;157:1453-9
44. Musgrave T, Verghese A. Clinical features of pneumonia in the elderly. Semin Respir Infect 1990;5:269-75
45. Torres A, El-Ebiary M, Riquelme R, et al. Communityacquired pneumonia in the elderly. Semin Respir Infect 1999;14:173-83
46. Riquelme R, Torres A, el-Ebiary M, et al. Communityacquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156:1908-14
47. Fernández-Sabé N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003;82:159-69
48. Basi SK, Marrie TJ, Huang JQ, et al. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004;117:305-11
49. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008;168:351-6
50. Kanwar M, Brar N, Khatib R, et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9
51. Pereira JM, Paiva JA, Rello J. Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med 2012;33:272-83
52. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82
53. Kabundji DM, Musekiwa A, Mukansi M, et al. Determining need for hospitalisation: Evaluation of the utility of the CRB-65 score in patients with communityacquired pneumonia presenting to an emergency department. S Afr Med J 2014;104:769-72
54. Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for communityacquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005;142:165-72
55. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530-4
56. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
57. Minnaard MC, de Groot JA, Hopstaken RM, et al. The added value of C-reactive protein measurement in diagnosing pneumonia in primary care: a meta-analysis of individual patient data. CMAJ 2016. [Epub ahead of print]
58. Smith RP, Lipworth BJ, Cree IA, et al. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995;108:1288-91
59. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in communityacquired pneumonia. Am J Med 2008;121:219-25
60. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;(9):CD007498
61. Ntusi N, Aubin L, Oliver S, et al. Guideline for the optimal use of blood cultures. S Afr Med J 2010;100:839-43
62. Chaisuksant S, Koonsuwan A, Sawanyawisuth K. Appropriateness of obtaining blood cultures in patients with community acquired pneumonia. Southeast Asian J Trop Med Public Health 2013;44:289-94
63. Campbell SG, McIvor RA, Joanis V, et al. Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures? World J Emerg Med 2011;2:272-8
64. Cham G, Yan S, Heng BH, et al. Predicting positive blood cultures in patients presenting with pneumonia at an Emergency Department in Singapore. Ann Acad Med Singap 2009;38:508-7
65. Falguera M, Trujillano J, Mene R, et al. A Prediction Rule for Estimating the Risk of Bacteremia in Patients with Community-Acquired Pneumonia. Clin Infect Dis 2009;49:409-16
66. Benenson RS, Kepner AM, Pyle D, et al. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007;33:1-8
67. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009;59:83-9
68. García-Vázquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004;164:1807-11
69. van dE, Vlaspolder F, de Graaff C, et al. Value of intensive diagnostic microbiological investigation in low-and highrisk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241-9
70. Gutiérrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003;36:286-92
71. Harris AM, Beekmann SE, Polgreen PM, et al. Rapid urine antigen testing for Streptococcus pneumoniae in adults with community-acquired pneumonia: clinical use and barriers. Diagn Microbiol Infect Dis 2014;79:454-7
72. Piso RJ, Iven-Koller D, Koller MT, et al. The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med Wkly 2012;142:w13679-9
73. Dunn JJ, Ginocchio CC. Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections? J Clin Microbiol 2015;53:1790-6
74. Liu YF, Gao Y, Chen M, et al. Etiological analysis and predictive diagnostic model building of communityacquired pneumonia in adult outpatients in Beijing, China. BMC Infect Dis 2013;13:309-9
75. Huijskens EG, Rossen JW, Kluytmans JA, et al. Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community-acquired pneumonia. Influenza Other Respir Viruses 2014;8:243-9
76. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21
77. Organization WH. Global tuberculosis report. 2014
78. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009;9:737-46
79. Pizzol D, Di Gennaro F, Chhaganlal KD, et al. Tuberculosis and diabetes: current state and future perspectives. Trop Med Int Health 2016;21:694-702
80. Calligaro GL, Theron G, Khalfey H, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med 2015;3:621-30
81. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:570-81
82. Steingart KR, Schiller I, Horne DJ, et al. Xpertâ® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;(1):CD009593
83. Peter JG, Theron G, Pooran A, et al. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Respir Med 2013;1:471-8
84. Wang SF, Ou XC, Li Q, et al. The Abbott RealTime MTB assay and the Cepheid GeneXpert assay show comparable performance for the detection of Mycobacterium tuberculosis in sputum specimens. Int J Infect Dis 2016;45:78-80
85. Seifert M, Ajbani K, Georghiou SB, et al. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016;20:631-7
86. World Health Organization. The use of molecular line probe assays for the detection of mutations associated with resistance to fluoroquinolones (FQs) and second-line injectable drugs (SLIDs). Policy Guidance 2016
87. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr 2009;52:145-51
88. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012;40:1211-20
89. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One 2013;8:e54875
90. Peter JG, Zijenah LS, Chanda D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIVpositive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016;387:1187-97
91. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98
92. Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002;20:982-9
93. Wakefield AE, Guiver L, Miller RF, et al. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet 1991;337:1378-9
94. Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992;340:203-6
95. Roux P, Lavrard I, Poirot JL, et al. Usefulness of PCR for detection of Pneumocystis carinii DNA. J Clin Microbiol 1994;32:2324-6
96. Flori P, Bellete B, Durand F, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004;53:603-7
97. Harris JR, Marston BJ, Sangrujee N, et al. Costeffectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One 2011;6:e23158
98. McTaggart LR, Wengenack NL, Richardson SE. Validation of the MycAssay Pneumocystis kit for detection of Pneumocystis jirovecii in bronchoalveolar lavage specimens by comparison to a laboratory standard of direct immunofluorescence microscopy, real-time PCR, or conventional PCR. J Clin Microbiol 2012;50:1856-9
99. Hauser PM, Bille J, Lass-Florl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011;49:1872-8
100. Wood BR, Komarow L, Zolopa AR, et al. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. Aids 2013;27:967-72
101. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988;137:796-800
102. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995;108:415-8
103. WHO. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland, 2007
104. Pakhale S, Mulpuru S, Verheij TJ, et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2014;(10):CD002109
105. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405
106. El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163:645-51
107. Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013;144:999-1007
108. Niederman MS. In the Clinic: Community-Acquired Pneumonia. Ann Intern Med 2015;163:ITC1-17
109. Belforti RK, Lagu T, Haessler S, et al. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Communityacquired Pneumonia. Clin Infect Dis 2016;63:1-9
110. Gattarello S, Borgatta B, Sole-Violan J, et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014;146:22-31
111. Gattarello S, Lagunes L, Vidaur L, et al. Improvement of antibiotic therapy and ICU survival in severe nonpneumococcal community-acquired pneumonia: a matched case-control study. Crit Care 2015;19:335-015-1051-1
112. Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014;42:420-32
113. Lee JS, Giesler DL, Gellad WF, et al. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA 2016;315:593-602
114. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:612-20
115. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-9
116. File TM, Garau J, Jacobs MR, et al. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with communityacquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Int J Antimicrob Agents 2005;25:110-9
117. File TM,Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010;51:1395-405
118. Ortiz-Ruiz G, Vetter N, Isaacs R, et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004;53 Suppl 2:ii59-66
119. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404
120. Noel ZR, Bastin ML, Montgomery AA, et al. Comparison of High-Dose Versus Standard Dose Oseltamivir in Critically Ill Patients With Influenza. J Intensive Care Med 2016. [Epub ahead of print]
121. NICD & NHLS. Healthcare Workers Handbook on Influenza 2015
122. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011;8:e1001053
123. Abadom TR, Smith AD, Tempia S, et al. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A casepopulation study. Vaccine 2016;34:5649-55
124. Wunderink RG, Mandell L. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2012;33:311-8
125. Meijvis SC, van de Garde EM, Rijkers GT, et al. Treatment with anti-inflammatory drugs in communityacquired pneumonia. J Intern Med 2012;272:25-35
126. Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med 2014;8:587-96
127. Chopra V, Rogers MA, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012;125:1111-23
128. Troeman DP, Postma DF, van Werkhoven CH, et al. The immunomodulatory effects of statins in communityacquired pneumonia: a systematic review. J Infect 2013;67:93-101
129. Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2013;8:e52929
130. Fitzgerald E, Duquette L, Williams M. Established statin use reduces mortality from community-acquired pneumonia:a systematic review and meta-analysis. EMJ Respir 2015;3:46-55
131. Viasus D, Garcia-Vidal C, Simonetti AF, et al. The effect of simvastatin on inflammatory cytokines in communityacquired pneumonia: a randomised, double-blind, placebocontrolled trial. BMJ Open 2015;5:e006251-2014-006251
132. Horita N, Otsuka T, Haranaga S, et al. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep 2015;5:14061
133. Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe communityacquired pneumonia patients. Eur Respir J 2015;45:463-72
134. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebocontrolled trial. Lancet 2015;385:1511-8
135. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86
136. Chen LP, Chen JH, Chen Y, et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. World J Emerg Med 2015;6:172-8
137. Marti C, Grosgurin O, Harbarth S, et al. Adjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0144032
138. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 2015;163:519-28
139. Wan YD, Sun TW, Liu ZQ, et al. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest 2016;149:209-19
140. Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 2016;8:E162-71
141. Popovic M, Blum CA, Nigro N, et al. Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients. Diabetologia 2016;59:2552-60
142. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41
143. Sligl WI, Eurich DT, Marrie TJ, et al. Age still matters: prognosticating short-and long-term mortality for critically ill patients with pneumonia. Crit Care Med 2010;38:2126-32
144. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228
145. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015;372:747-55
146. Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for communityacquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012;(9):CD004418
147. Muthuri SG, Venkatesan S, Myles PR, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data metaanalysis. Influenza Other Respir Viruses 2016;10:192-204
148. Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in followup of severe community-acquired pneumonia. Rev Port Pneumol 2009;15:129-32
149. Nathwani D, Lawson W, Dryden M, et al. Implementing criteria-based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect 2015;21 Suppl 2:S47-55
150. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;333:1193
151. Engel MF, Bruns AH, Hulscher ME, et al. A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study. Eur J Clin Microbiol Infect Dis 2014;33:1897-908
152. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med 1980;69:507-12
153. Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13
154. Wilcox ME, Chong CA, Stanbrook MB, et al. Does this patient have an exudative pleural effusion? The Rational Clinical Examination systematic review. JAMA 2014;311:2422-31
155. Good JT Jr, Taryle DA, Maulitz RM, et al. The diagnostic value of pleural fluid pH. Chest 1980;78:55-9
156. Houston MC. Pleural fluid pH: diagnostic, therapeutic, and prognostic value. Am J Surg 1987;154:333-7
157. Seedat MA, Feldman C, Skoularigis J, et al. A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993;86:669-75
158. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007;45:158-65
159. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008;47:182-7
160. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011;8:e1001048
161. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125:773-81
162. Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. Lancet 2013;381:496-505
163. Soto-Gomez N, Anzueto A, Waterer GW, et al. Pneumonia: an arrhythmogenic disease? Am J Med 2013;126:43-8
164. Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014;64:1917-25
165. Feldman C, Anderson R. Community-Acquired Pneumonia: Pathogenesis of Acute Cardiac Events and Potential Adjunctive Therapies. Chest 2015;148:523-32
166. Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc 2015;4:e001595
167. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014;10:e1004383
168. Brown AO, Millett ER, Quint JK, et al. Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 2015;191:739-45
169. Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013;66:27-33
170. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264-74
171. Cangemi R, Calvieri C, Falcone M, et al. Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. Am J Cardiol 2015;116:647-51
172. Feldman C, Anderson R. Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care 2016;22:477-84
173. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665-71
174. Lode H. Microbiological and clinical aspects of aspiration pneumonia. J Antimicrob Chemother 1988;21 Suppl C:83-90
175. Bartlett JG, Gorbach SL. The triple threat of aspiration pneumonia. Chest 1975;68:560-6
176. Finegold SM. Aspiration pneumonia. Rev Infect Dis 1991;13 Suppl 9:S737-42
177. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-4
178. Mullan H, Roubenoff RA, Roubenoff R. Risk of pulmonary aspiration among patients receiving enteral nutrition support. JPEN J Parenter Enteral Nutr 1992;16:160-4
179. DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. J Crit Care 2015;30:40-8
180. Lipper B, Simon D, Cerrone F. Pulmonary aspiration during emergency endoscopy in patients with upper gastrointestinal hemorrhage. Crit Care Med 1991;19:330-3
181. Rudolph SJ, Landsverk BK, Freeman ML. Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage. Gastrointest Endosc 2003;57:58-61
182. Reza Shariatzadeh M, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006;54:296-302
183. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99
184. Torres A, Serra-Batlles J, Ferrer A, et al. Severe communityacquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8
185. Moine P, Vercken JB, Chevret S, et al. Severe communityacquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994;105:1487-95
186. Taylor JK, Fleming GB, Singanayagam A, et al. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. Am J Med 2013;126:995-1001
187. Holas MA, DePippo KL, Reding MJ. Aspiration and relative risk of medical complications following stroke. Arch Neurol 1994;51:1051-3
188. Westendorp WF, Nederkoorn PJ, Vermeij JD, et al. Poststroke infection: a systematic review and meta-analysis. BMC Neurol 2011;11:110
189. Leroy O, Vandenbussche C, Coffinier C, et al. Communityacquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997;156:1922-9
190. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:24-31
191. Kozlow JH, Berenholtz SM, Garrett E, et al. Epidemiology and impact of aspiration pneumonia in patients undergoing surgery in Maryland, 1999-2000. Crit Care Med 2003;31:1930-7
192. Adnet F, Baud F. Relation between Glasgow Coma Scale and aspiration pneumonia. Lancet 1996;348:123-4
193. Mokhlesi B, Logemann JA, Rademaker AW, et al. Oropharyngeal deglutition in stable COPD. Chest 2002;121:361-9
194. Nosè M, Recla E, Trifirò G, et al. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2015;24:812-20
195. Terpenning MS, Taylor GW, Lopatin DE, et al. Aspiration pneumonia: dental and oral risk factors in an older veteran population. J Am Geriatr Soc 2001;49:557-63
196. Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a national sample survey population. Ann Periodontol 1998;3:251-6
197. Park RH, Allison MC, Lang J, et al. Randomised comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with persisting neurological dysphagia. BMJ 1992;304:1406-9
198. Bartlett JG. How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy. Infect Dis Clin North Am 2013;27:149-55
199. Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993;16 Suppl 4:S248-55
200. Finegold SM, George WL, Mulligan ME. Anaerobic infections. Part I. Dis Mon 1985;31:1-77
201. Moser KM, Maurer J, Jassy L, et al. Sensitivity, specificity, and risk of diagnostic procedures in a canine model of Streptococcus pneumoniae pneumonia. Am Rev Respir Dis 1982;125:436-42
202. Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993;19:279-84
203. Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999;115:178-83
204. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650-4
205. El-Solh AA, Vora H, Knight PR 3rd, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med 2011;39:1251-6
206. Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. Am Rev Respir Dis 1974;110:56-77
207. Mendelson CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol 1946;52:191-205
208. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983;98:466-71
209. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990;150:2525-9
210. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102-6
211. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012;61:394-5
212. Pfizer laboratories (Pty) Ltd. Prevenar 13 suspension for injection. Final approved Package Insert-26 November 2015
213. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-9
214. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822-5
215. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812-22
216. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-25
217. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635-45
218. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011;52:128-37